Ono Pharmaceutical Co., Ltd. (4528.T)
| Previous close | 2,324.00 |
| Open | 2,344.50 |
| Bid | 2,298.00 x 0 |
| Ask | 2,305.50 x 0 |
| Day's range | 2,293.50 - 2,344.50 |
| 52-week range | 2,232.50 - 2,966.50 |
| Volume | |
| Avg. volume | 2,180,866 |
| Market cap | 1.083T |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 8.73 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 80.00 (3.47%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, "Deciphera") today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer follow
- PR Newswire
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P. ("OVI FI"), which was established as a corporate venture capital fund in CA, USA in May 2020.
